Aardvark Therapeutics, Inc. Common Stock (AARD)
PHARMACEUTICAL PREPARATIONS
Aardvark Therapeutics, Inc. Common Stock (AARD) is listed on Nasdaq, where it has traded since February 13, 2025.
- Listed On
- Nasdaq
- Listed Since
- February 13, 2025
- Employees
- 28
- Market Cap
- $26M
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 70 institutions reported holding AARD, with 9.4 million shares worth $54.3 million in aggregate. The largest reported holder was Decheng Capital, with 3.9 million shares worth $22.6 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Decheng Capital | 3,917,299 | $23M | Unchanged |
| Citadel Advisors | 1,283,166 | $7M | Added 3.25% |
| Laurion Capital Management | 1,034,459 | $6M | Unchanged |
| Vanguard | 643,942 | $4M | Added 0.11% |
| AQR Capital Management | 480,249 | $3M | Added 257.08% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is AARD?
Aardvark Therapeutics, Inc. Common Stock (AARD) is listed on Nasdaq, where it has traded since February 13, 2025.
Who are the largest institutional holders of AARD?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of AARD were Decheng Capital, Citadel Advisors and Laurion Capital Management.
How many institutions own AARD?
70 institutions reported a position in AARD for the quarter ended June 30, 2026, worth $54.3 million in total.
Did institutions buy or sell AARD last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for AARD.
Every reported institutional holder, plus insider and congressional trades in AARD, on SentiSense.